Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million
CompanyDeals

Zai Lab Ltd Announces Secondary Public Offering Worth $230 Million

AstraZeneca's Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC
CompanyDrug

AstraZeneca’s Tagrisso Receives Positive CHMP Opinion for EGFR-Mutated NSCLC

Everest Medicines' Nefecon Receives Full Approval from South Korea's MFDS for IgAN Treatment
CompanyDrug

Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment

Eli Lilly's Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study
CompanyDrug

Eli Lilly’s Muvalaplin Demonstrates Potent Lp(a) Reduction in Phase II Study

Sunshine Guojian Pharmaceutical's SSGJ-608 Files for NMPA Approval in Plaque Psoriasis
CompanyDrug

Sunshine Guojian Pharmaceutical’s SSGJ-608 Files for NMPA Approval in Plaque Psoriasis

Huahui Health's Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus
CompanyDrug

Huahui Health’s Libevitug Earns FDA Breakthrough Designation for Chronic Hepatitis Delta Virus

Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status
CompanyMedical Device

Xeltis AG Enrolls First Patient in US Pivotal Trial for aXess with FDA BTD Status

Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing
CompanyDeals

Shanghai Leadingtac Pharmaceutical Secures $13.81 Million in Series A Financing

Huadong Medicine's DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials
CompanyDrug

Huadong Medicine’s DR10624 Receives NMPA Approval for MAFLD and MASH Clinical Trials

NMPA's CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation
Policy / Regulatory

NMPA’s CDE Issues Guidelines for Leveraging Real-World Data in Drug Regulation

Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502
CompanyDeals

Biosion Secures Licensing Deal with Aclaris Therapeutics for Global Rights to BSI-045B and BSI-502

Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer
CompanyDeals

Ratio Therapeutics Partners with Novartis on SSTR2 Radiotherapeutic for Cancer